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Abstract 
Background: The diagnosis of invasive pulmonary aspergillosis is challenging. It is unclear whether galactomannan 
(GM) results from bronchial wash (BW) and bronchoalveolar lavage (BAL) samples differ in a clinically meaningful way.
Results: Ninety-six paired (BAL and BW) samples from 85 patients were included. The average age was 53 years, 
61 % of the patients were male, and 74.1 % had an underlying diagnosis of AML/MDS (ALL 7.1 %, other hematologic 
malignancy 18.8 %). 57 (67.1 %) patients were neutropenic, and 56 (65.9 %) patients were receiving mold-active drugs 
at least 48 h prior to bronchoscopy. The overall agreement between GM detection from BW and BAL was 63.5 % 
(K = 0.152; 95 % CI 0.008–0.311) and 73 % (K = 0.149; 95 % CI 0.048–0.348) at cut off ≥0.5 and ≥1.0, respectively. 
Among 43 positive samples, using a GM cut-off of 0.5, 39 (90.5 %) were positive in BW samples whereas 12 (29.3 %) 
were positive in BAL samples. The median level of GM in BW (0.28) samples was significantly higher than in BAL (0.20) 
samples among 53 samples with negative results (P = 0.001). There was no statistically significant difference in the 
median GM values between the BW and BAL samples with positive results (P = 0.08). There was no significant dif-
ference in GM detection between samples with positive and negative results with regard to antifungal, beta lactam 
antibacterial treatment or neutropenia (60.5 vs 56.6 %; 53.9 vs 46 %; 65.1 vs 54.7 %, respectively).
Conclusion: This retrospective study examining two collection techniques suggests that BW may have higher diag-
nostic yield compared to bronchoalveolar lavage for GM detection.
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Findings
The mortality rate of invasive pulmonary aspergillosis 
(IPA) remains high in part due to barriers to early diag-
nosis [1–3]. A definite diagnosis of IPA requires histo-
logical evidence of invasive disease or positive cultures 
from sterile sites [4]. However, respiratory cultures have 
poor sensitivity and tissue biopsy is not always feasible 
[5, 6]. Therefore, current diagnostic approaches include 
non-culture/histopathologic modalities including com-
bination of chest CT imaging and non-invasive, non-
culture based tools such as galactomannan (GM) antigen 
detection in bronchoalveolar lavage (BAL) and bronchial 
wash (BW) [7–11]. BW samples are defined as the first 
obtained aliquot of BAL fluid after instillation of small 
amount of saline into a major airway; BAL samples are 
collected from the distal bronchioles and alveoli follow-
ing instillation of a large volume of saline often greater 
than 140 ml in several aliquots [12]. It is unclear whether 
GM results from BW and BAL samples differ in a clini-
cally meaningful way. It is hypothesized that bronchial 
airways may contain more aspergillus hyphae with more 
subsequent GM release than in alveoli. Alternatively, GM 
in BAL fluid may be diluted by lavage to an undetectable 
level by ELISA [13, 14].
In this study, we aimed to compare the performance 
characteristics of GM antigen tests obtained from BW 
and BAL samples. This retrospective study included 
all adult patients with hematologic malignancies at the 
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who underwent bronchoscopy for evaluation of new pul-
monary infiltrates while receiving broad spectrum anti-
biotics or progression of existing lung infiltrates from 
October 2010 to September 2013. Only patients who 
had concurrent paired BAL and BW samples separately 
tested for GM antigen during the same procedure were 
included. The Platelia Aspergillus enzyme immunoas-
say (Bio-Rad Laboratories, Hercules, CA, USA) was used 
to measure GM antigen levels, using different cutoffs 
for positivity (≥0.5 and  ≥1). A patient who underwent 
repeated sampling in separate bronchoscopic procedures 
was included in the analysis if bronchoscopy had been 
performed on the basis of a new pulmonary infiltrate at 
least 2 months after the first procedure. Plasmalyte solu-
tion was not used to perform BAL. Kappa statistics were 
used to assess the agreement between the GM results 
obtained from BW and BAL samples. The Wilcoxon test 
and McNemar’s test were used, as appropriate. All data 
analyses were performed using SAS V.8.0. 96 paired 
samples (BAL and BW) were analyzed from 85 patients 
(AML/MDS 74.12 %, ALL 7.06 % and the others 18.82 %) 
comprising 52 males and 33 females with an average age 
of 53  years (range 20–81). 57 (67.06  %) patients were 
neutropenic (absolute neutrophil count <500//mm3) and 
56 patients (58.3 %) were receiving mold-active drugs at 
least 48  h prior to bronchoscopy. Piperacillin-tazobac-
tam was used in nine patients, none had a positive GM 
test from BAL or BW. Concurrent serum GM assays 
were performed in only 14 patients (16  %) and three of 
which were positive at a cutoff ≥0.5. Of these three, all 
three were positive in samples collected by BW but only 
one was positive in samples collected by BAL (using 
OD cutoff value of ≥0.5). Of the 11 negative serum GM 
results, four were positive by BW samples alone, and one 
was positive by BAL sample alone; the remainder were 
negative by both BAL and BW. Of the total four culture-
positive BAL samples, one yielded aspergillus fumigatus 
(with a GM of ≥1 from both BAL and BW), and three 
yielded penicillium species, of which only one had a posi-
tive GM >0.5 from BW sample alone.
The overall agreement between GM detection from 
BW and BAL was 63.5  % (K  =  0.152; 95  % CI 0.008–
0.311) and 73  % (K =  0.149; 95  % CI 0.048–0.348) at a 
diagnostic cut off ≥0.5 and ≥1.0, respectively. Among 43 
positive samples, using a GM cut-off of 0.5, 39 (90.5 %) 
were positive in BW samples whereas 12 (29.3  %) were 
positive in BAL samples. The GM assay performance 
for BW and BAL fluid samples for different cut-off OD 
indexes is shown in Table 1.
The median levels of GM in BW (0.28) samples were 
significantly higher than in BAL (0.20) samples among 53 
samples with negative results (P = 0.001). Though there 
was no statistically significant difference in median GM 
values between the BW and BAL samples with positive 
results (median OD index of 1.3 for the BW samples vs 
3.5 for the BAL samples, P =  0.08), there was a higher 
number of positive GM results (OD index cut-off of 
0.5) only detectable by BW (54.1  %) compared to those 
detectable only by BAL (9.3 %, P < 0.0001). There was no 
significant difference in GM detection between samples 
with positive and negative results with regard to anti-
fungal, antibacterial treatment or neutropenia (60.5 vs 
56.6 %; 53.9 vs 46 %; 65.1 vs 54.7 %, respectively).
Conclusions
To our knowledge only two studies have compared GM 
antigen detection yield in BAL and BW with conflicting 
results [15, 16]. Similar to the results observed by Sey-
farth et  al., our study demonstrated that BW and BAL 
results are not comparable in terms of detection of GM 
[15].
The poor concordance between the results of GM 
detection from the two sample methods in our retro-
spective single center study suggests that the addition 
of BW to BAL GM detection enhances positive results 
or it might be a better single diagnostic sample for GM 
antigen detection. However, we were unable to establish 
test specificity/sensitivity due to lack of a gold standard, 
insensitivity of aspergillus species culture and lack of 
concurrent serum GM assay (proven and probable cases). 
Further studies are needed to confirm the complemen-
tary role of the BW and to evaluate sensitivity, specificity 
of GM detection in BW and BAL in IPA diagnosis.
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Table 1 Frequency of  positive galactomannan antigen 
in  BAL or BW samples at  different cut-off galactomannan 
OD indexes
OD optical density, BAL bronchoalveolar lavage, BW bronchial washing, GM 
galactomannan
Sample, n = 96 BAL+, total BW+, total BAL+ or BW+
GM index ≥ 0.5 12 (12.5 %) 39 (40. 62 %) 43 (44.79 %)
GM index ≥ 1.0 10 (10.42 %) 26 (27.08 %) 31 (32.29 %)
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